Treatment of L-DOPA-induced Dyskinesia in Parkinson’s Disease

Summary of the technology

Repurposed antidepressant agents for treating levodopa-induced dyskinesia (LID) in Parkinson's disease dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.

Binghamton University

Details of the Technology Offer


Dopamine replacement therapy with L-DOPA remains the gold-standard treatment for the crippling movement disruptions affecting >10 million Parkinson’s Disease patients worldwide. However, L-DOPA therapies, especially after prolonged use, are associated with painful and disabling abnormal involuntary movements termed L-DOPA induced dyskinesia (LID), which affect nearly 90% of patients within 10 years of commencing treatment. An estimated >2 million Parkinson’s disease patients worldwide will exhibit extremely disruptive LID this year alone.

Given that L-DOPA remains the most effective Parkinson’s treatment option, substantial research has focused on addressing this problem, yet without much success in the translation to the clinical setting. Recently, amantadine has become the first drug to be repurposed and approved for LID mitigation, but has encountered roadblocks in the clinic, including limited efficacy and major side effects.

Technology Overview

Binghamton University researchers have developed a new method for treating LID in Parkinson’s disease, demonstrating for the first time the anti-dyskinetic potential of dual partial 5-HT1A agonist/SSRI agents, including the FDA-approved antidepressants vilazodone (Viibryd) and vortioxetine (Trintellix). The dual-activity antidepressants dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.


  • More effective than currently approved therapy.
  • Potent and stable response.
  • Reduced side effect profile.
  • FDA-approved compounds positioned for rapid repurposing.
  • Effective in prevention and treatment of LID in Parkinson’s patients.

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Neurology, Brain Research
  • Pharmaceutical Products / Drugs
  • Medical Health related
  • Therapeutic
  • neuroscience
  • parkison's disease

About Binghamton University

The best public university in the Northeast.

A world-class institution, Binghamton University offers students a broad, interdisciplinary education with an international perspective and one of the most vibrant research programs in the nation.

Ranked among the elite public universities in the country, Binghamton challenges students academically, not financially, in its unique, best-of-both-worlds environment.

Our academic culture rivals a first-rate private university — rigorous, collaborative and boldly innovative — while our campus culture exemplifies the best kind of public university experience: richly diverse students, active social life and deep engagement with the community.

Our students, both undergraduate and graduate, work one-on-one with an exceptional faculty and groundbreaking scholars. They take advantage of special academic opportunities like combined degrees, foreign language study groups and an unparalleled international education program.

Fabiola Moreno

Never miss an update from Fabiola Moreno

Create your free account to connect with Fabiola Moreno and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Fabiola

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support